Waisberg J, Saba GT. Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol 2015; 7(26): 2631-2635 [PMID: 26609340 DOI: 10.4254/wjh.v7.i26.2631]
Corresponding Author of This Article
Jaques Waisberg, MD, PhD, FACS, Professor, Head, Department of Surgery, ABC Medical School, Santo André, São Paulo 09060-650, Brazil. jaqueswaisberg@uol.com.br
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Nov 18, 2015; 7(26): 2631-2635 Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2631
Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma
Jaques Waisberg, Gabriela Tognini Saba
Jaques Waisberg, Department of Surgery, Hospital do Servidor Público Estadual de São Paulo (IAMSPE), São Paulo 09060-650, Brazil
Jaques Waisberg, Gabriela Tognini Saba, Department of Surgery, ABC Medical School, Santo André, São Paulo 09060-650, Brazil
Author contributions: Waisberg J and Saba GT contributed equally to this work.
Conflict-of-interest statement: The authors have no conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jaques Waisberg, MD, PhD, FACS, Professor, Head, Department of Surgery, ABC Medical School, Santo André, São Paulo 09060-650, Brazil. jaqueswaisberg@uol.com.br
Telephone: +55-11-982560018 Fax: +55-11-44368739
Received: May 28, 2015 Peer-review started: June 1, 2015 First decision: July 27, 2015 Revised: October 12, 2015 Accepted: November 3, 2015 Article in press: November 4, 2015 Published online: November 18, 2015 Processing time: 174 Days and 4.6 Hours
Core Tip
Core tip: The Wnt signaling pathway is decisive in the rule of mechanisms of proliferation and survival, as well as the differentiation of liver cells during hepatic embryogenesis and morphogenesis. The atypical initiation of signaling in the hepatocellular carcinoma (HCC) is primarily because of deregulated expressions of the components of the Wnt-/-β-catenin. The mechanisms that are considered more functional and that sustain aberrant activation of signaling pathways act via alterations in the β-catenin gene or the AXIN1/2-gene’s encoding axin, a protein necessary for the degradation of β-catenin. The development of targeted therapeutic molecules for the blockade of the Wnt-signaling pathway for the treatment of HCC depends on the identification of molecules that would be effective only in tumor cells that carry an aberrant signaling β-catenin.
